Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From mutation to management: Advancing Langerhans cell histiocytosis treatment through combination therapies.

British journal of haematology - 1 May 2024

Diamond Akiva

Abstract excerpt

The treatment landscape for relapsed Langerhans cell histiocytosis (LCH) is fraught with uncertainty due to a scarcity of data. Karri et al.'s study provides promising evidence that combining MAPK pathway inhibitors with chemotherapy could improve outcomes, even for patients with multiple relapses. Although larger studies are needed, this approach suggests a shift towards more aggressive, potentially curative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Disease Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histiocytosis, Langerhans-Cell

Share to MAP Kinase Signaling System

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 38606542
DOI: 10.1111/bjh.19473

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From mutation to management: Advancing Langerhans cell histiocytosis treatment through combination therapies.PMID 38606542Read ↗

Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosisSemantic proximity Read ↗

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.Semantic proximity Read ↗

Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.Semantic proximity Read ↗

Clinical features and treatment of Langerhans cell histiocytosis.Semantic proximity Read ↗

Beyond BRAFV600E: Investigating the Clinical and Genetic Spectrum of Langerhans Cell Histiocytosis in Children.Semantic proximity Read ↗

BRAF deletion in adult patients with Langerhans cell histiocytosis correlates with multisystem disease and poor outcomeSemantic proximity Read ↗

BRAF Deletion in Adult Patients with Langerhans Cell Histiocytosis Correlates with Multisystem Disease and Poor Outcomes.Semantic proximity Read ↗

Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.Semantic proximity Read ↗

Clinical characteristics, genomic profiling, treatments, and outcomes of Langerhans cell sarcoma.Semantic proximity Read ↗

Langerhans cell histiocytosis: Version 2021Semantic proximity Read ↗

Clinical characteristics, genomic profiling, treatments, and outcomes of Langerhans Cell SarcomaSemantic proximity Read ↗

Targeted therapy for Langerhans cell histiocytosis with maxillofacial involvement in 20 children.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.